About Osteotech

Osteotech, Inc. is a global leader in the processing of human bone and connective tissue for transplantation and an innovator in the development, manufacturing, and marketing of biologic, biomaterial, and device systems for musculoskeletal surgery. With a particular focus on spinal, trauma, and total joint revision procedures, the Company's current and development-stage technologies address needs within numerous musculoskeletal disciplines.

Since its formation in 1986, the Company has become the world's largest processor of aseptic allograft bone tissue, yielding over 4 million grafts. Used in spinal fusions, to replace cancerous tissue, fill voids caused by trauma, augment prostheses, and replace damaged ligaments and tendons, bone tissues processed by Osteotech improve the quality of life for more than 500 transplant recipients every day. The Company processes and distributes transplant bone, ligaments, and tendons. In addition, the Company has expanded globally through its subsidiary OST Development.

Osteotech continues to develop a series of human tissue technologies for use in musculoskeletal surgery. The first such technology, Grafton® Demineralized Bone Matrix (DBM) Gel, was introduced in mid-1991. SInce then, Osetotech developed and patented Bone Fiber Technology and to date is still the only company to produce DBM from bone fibers. All Grafton DBM forms help form bone through osteoconduction and osteoinduction and are processed in a manner that has been scientifically validated to be virally inactivated. To date, the Company's Grafton DBM forms have been used in over 800,000 surgical procedures by more than 4,000 transplant professionals, worldwide.

Visit the Osteotech Corporate Web Site.